Vitamin D receptor Inhibitors
1 drugsAbout Vitamin D receptor
The Vitamin D receptor (VDR) is a nuclear receptor protein that regulates gene expression in response to vitamin D. As a ligand-activated transcription factor, VDR modulates transcription of target genes involved in calcium homeostasis and bone metabolism.
VDR is a potential drug target influencing various physiological processes. Currently, there is no genetic evidence directly linking the Vitamin D receptor to specific diseases in this dataset.
VDR is targeted by one FDA-approved drug, RAYALDEE, a small molecule approved in 2016. EIRGEN is the sole company with an approved VDR-targeting drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Critically Ill with only 1 trials.
Top Vitamin D receptor Drugs
EIRGEN is the only company with an approved drug targeting VDR.
Low competition suggests easier market entry, but also highlights potential risks due to limited validation.
Vitamin D receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Vitamin D receptor, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for novel approaches like antibodies or peptides.
Vitamin D receptor Clinical Trials 11 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 5 | 4 | 1 | 0 | 80% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 5 | 4 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Vitamin D receptor Drug Approval Timeline (2016 - 2016)
RAYALDEE was the first and most recent approved drug in 2016.
The single approval suggests a potentially unsaturated market, but also highlights challenges in developing VDR-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (13 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 15 clinical trials targeting Vitamin D receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities